U.S. markets closed

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1100-0.0500 (-4.31%)
At close: 4:00PM EDT

1.0800 -0.03 (-2.70%)
After hours: 7:59PM EDT

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place
The Woodlands, TX 77381-1160
United States
281 863 3000

Full Time Employees184

Key Executives

NameTitlePayExercisedYear Born
Mr. Lonnel CoatsPres, CEO & Director1.12MN/A1965
Mr. Jeffrey L. WadeExec. VP of Corp. & Admin. Affairs and CFO638.36kN/A1965
Dr. Praveen TyleExec. VP of R&D679.65kN/A1960
Dr. Robert J. LefkowitzConsultant & Independent Director44.64kN/A1944
Mr. James F. TessmerVP of Fin. & AccountingN/AN/A1960
Dr. Kimberly LeeHead of Investor Relations & Corp. StrategyN/AN/AN/A
Mr. Brian T. CrumVP, Gen. Counsel & Sec.N/AN/A1973
Chas SchultzExec. Director of Corp. Communications & Patient AdvocacyN/AN/AN/A
Dr. Alan J. MainExec. VP of Commercial Supply OperationsN/AN/A1954
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 31, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.